Maraviroc (UK-427,857), a Potent, Orally Bioavailable, and Selective Small-Molecule Inhibitor of Chemokine Receptor CCR5 with Broad-Spectrum Anti-Human Immunodeficiency Virus Type 1 Activity

ABSTRACT Maraviroc (UK-427,857) is a selective CCR5 antagonist with potent anti-human immunodeficiency virus type 1 (HIV-1) activity and favorable pharmacological properties. Maraviroc is the product of a medicinal chemistry effort initiated following identification of an imidazopyridine CCR5 ligand from a high-throughput screen of the Pfizer compound file. Maraviroc demonstrated potent antiviral activity against all CCR5-tropic HIV-1 viruses tested, including 43 primary isolates from various clades and diverse geographic origin (geometric mean 90% inhibitory concentration of 2.0 nM). Maraviroc was active against 200 clinically derived HIV-1 envelope-recombinant pseudoviruses, 100 of which were derived from viruses resistant to existing drug classes. There was little difference in the sensitivity of the 200 viruses to maraviroc, as illustrated by the biological cutoff in this assay (= geometric mean plus two standard deviations [SD] of 1.7-fold). The mechanism of action of maraviroc was established using cell-based assays, where it blocked binding of viral envelope, gp120, to CCR5 to prevent the membrane fusion events necessary for viral entry. Maraviroc did not affect CCR5 cell surface levels or associated intracellular signaling, confirming it as a functional antagonist of CCR5. Maraviroc has no detectable in vitro cytotoxicity and is highly selective for CCR5, as confirmed against a wide range of receptors and enzymes, including the hERG ion channel (50% inhibitory concentration, >10 μM), indicating potential for an excellent clinical safety profile. Studies in preclinical in vitro and in vivo models predicted maraviroc to have human pharmacokinetics consistent with once- or twice-daily dosing following oral administration. Clinical trials are ongoing to further investigate the potential of using maraviroc for the treatment of HIV-1 infection and AIDS.

[1]  M. Prichard,et al.  A three-dimensional model to analyze drug-drug interactions. , 1990, Antiviral research.

[2]  S. Arya,et al.  Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. , 1995, Science.

[3]  Hiroko Tanaka,et al.  The effect of a synthetic 7‐thiaprostaglandin E1 derivative, TEI‐6122, on monocyte chemoattractant protein‐1 induced chemotaxis in THP‐1 cells , 1995, British journal of pharmacology.

[4]  S. Arya,et al.  Identification of RANTES, MIP-1α, and MIP-1β as the Major HIV-Suppressive Factors Produced by CD8+ T Cells , 1995, Science.

[5]  J J Goedert,et al.  Genetic Restriction of HIV-1 Infection and Progression to AIDS by a Deletion Allele of the CKR5 Structural Gene , 1996, Science.

[6]  Richard A Koup,et al.  Homozygous Defect in HIV-1 Coreceptor Accounts for Resistance of Some Multiply-Exposed Individuals to HIV-1 Infection , 1996, Cell.

[7]  Virginia Litwin,et al.  HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5 , 1996, Nature.

[8]  Marc Parmentier,et al.  Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene , 1996, Nature.

[9]  R. Bravo,et al.  Impaired macrophage function and enhanced T cell-dependent immune response in mice lacking CCR5, the mouse homologue of the major HIV-1 coreceptor. , 1998, Journal of immunology.

[10]  T. Merigan,et al.  Human Immunodeficiency Virus Type 1 Protease Genotypes and In Vitro Protease Inhibitor Susceptibilities of Isolates from Individuals Who Were Switched to Other Protease Inhibitors after Long-Term Saquinavir Treatment , 1998, Journal of Virology.

[11]  M. Scheinin,et al.  Subtype-specific stimulation of []GTPγS binding by recombinant α2-adrenoceptors , 1998 .

[12]  J. Boyd,et al.  Identification of C-C Chemokine Receptor 1 (CCR1) as the Monocyte Hemofiltrate C-C Chemokine (HCC)-1 Receptor , 1998, The Journal of experimental medicine.

[13]  M. Mack,et al.  Aminooxypentane-RANTES Induces CCR5 Internalization but Inhibits Recycling: A Novel Inhibitory Mechanism of HIV Infectivity , 1998, The Journal of experimental medicine.

[14]  James G. Boyd,et al.  Interferon–inducible T Cell Alpha Chemoattractant (I-TAC): A Novel Non-ELR CXC Chemokine with Potent Activity on Activated T Cells through Selective High Affinity Binding to CXCR3 , 1998, The Journal of experimental medicine.

[15]  M. Scheinin,et al.  Subtype-specific stimulation of [35S]GTPgammaS binding by recombinant alpha2-adrenoceptors. , 1998, European journal of pharmacology.

[16]  E. De Clercq.  The emerging role of fusion inhibitors in HIV infection. , 1999, Drugs in R&D.

[17]  Andrew W. Liu,et al.  MHC class II tetramers identify peptide-specific human CD4(+) T cells proliferating in response to influenza A antigen. , 1999, The Journal of clinical investigation.

[18]  S. Yerly,et al.  Transmission of antiretroviral-drug-resistant HIV-1 variants , 1999, The Lancet.

[19]  J. Farber,et al.  Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. , 1999, Annual review of immunology.

[20]  Pascal Poignard,et al.  Highly Potent RANTES Analogues either Prevent CCR5-Using Human Immunodeficiency Virus Type 1 Infection In Vivo or Rapidly Select for CXCR4-Using Variants , 1999, Journal of Virology.

[21]  M. Scheinin,et al.  Alpha2-adrenoceptor agonists stimulate high-affinity GTPase activity in a receptor subtype-selective manner. , 1999, European journal of pharmacology.

[22]  S. O’Brien,et al.  The effect of genetic variation in chemokines and their receptorson HIV transmission and progression to AIDS , 2000, Immunological reviews.

[23]  John P. Moore,et al.  Use of Inhibitors To Evaluate Coreceptor Usage by Simian and Simian/Human Immunodeficiency Viruses and Human Immunodeficiency Virus Type 2 in Primary Cells , 2000, Journal of Virology.

[24]  C. Sabin,et al.  The effects of the 32‐bp CCR‐5 deletion on HIV transmission and HIV disease progression in individuals with haemophilia , 2000, British journal of haematology.

[25]  J. Margolick,et al.  Causal Pathways for CCR5 Genotype and HIV Progression , 2000, Journal of acquired immune deficiency syndromes.

[26]  G. Shaw,et al.  Sensitivity of Human Immunodeficiency Virus Type 1 to Fusion Inhibitors Targeted to the gp41 First Heptad Repeat Involves Distinct Regions of gp41 and Is Consistently Modulated by gp120 Interactions with the Coreceptor , 2001, Journal of Virology.

[27]  J P Bru,et al.  Acute HIV infection: impact on the spread of HIV and transmission of drug resistance , 2001, AIDS.

[28]  Serena Xu,et al.  SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[29]  H. Brühl,et al.  Depletion of CCR5-Expressing Cells with Bispecific Antibodies and Chemokine Toxins: A New Strategy in the Treatment of Chronic Inflammatory Diseases and HIV , 2001, The Journal of Immunology.

[30]  Hiroaki Mitsuya,et al.  Novel Low Molecular Weight Spirodiketopiperazine Derivatives Potently Inhibit R5 HIV-1 Infection through Their Antagonistic Effects on CCR5* , 2001, The Journal of Biological Chemistry.

[31]  Jun Zhou,et al.  Blockade of human cardiac potassium channel human ether-a-go-go-related gene (HERG) by macrolide antibiotics. , 2002, The Journal of pharmacology and experimental therapeutics.

[32]  Elizabeth Connick,et al.  Antiretroviral-drug resistance among patients recently infected with HIV. , 2002, The New England journal of medicine.

[33]  J. McKeating,et al.  Pharmacological characterization of the chemokine receptor, CCR5 , 2002, British journal of pharmacology.

[34]  T. Kenakin,et al.  CCR5 chemokine receptors: gatekeepers of HIV-1 infection. , 2002, Current drug targets. Infectious disorders.

[35]  R. Lal,et al.  Susceptibility of diverse primary HIV isolates with varying co‐receptor specificity's to CXCR4 antagonistic compounds , 2002, Journal of medical virology.

[36]  C. Supuran,et al.  Non-peptidic Chemokine Receptors Antagonists as Emerging Anti-HIV Agents , 2002, Journal of enzyme inhibition and medicinal chemistry.

[37]  M. Paterlini,et al.  Structure modeling of the chemokine receptor CCR5: implications for ligand binding and selectivity. , 2002, Biophysical journal.

[38]  A. Trkola,et al.  HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[39]  J. Ickovics,et al.  Adherence to HAART among patients with HIV: Breakthroughs and barriers , 2002, AIDS care.

[40]  N. Meanwell,et al.  Biochemical and Genetic Characterizations of a Novel Human Immunodeficiency Virus Type 1 Inhibitor That Blocks gp120-CD4 Interactions , 2003, Journal of Virology.

[41]  John H Elder,et al.  Is resistance futile? , 2003, Current drug targets. Infectious disorders.

[42]  S. Yerly,et al.  Travel and the spread of HIV-1 genetic variants. , 2003, The Lancet. Infectious diseases.

[43]  N. Meanwell,et al.  Inhibitors of the entry of HIV into host cells. , 2003, Current opinion in drug discovery & development.

[44]  Zheng Yang,et al.  A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[45]  D. Richman,et al.  Rapid evolution of the neutralizing antibody response to HIV type 1 infection , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[46]  Chris G Barber.  CCR5 antagonists for the treatment of HIV. , 2004, Current opinion in investigational drugs.

[47]  C. Petropoulos,et al.  Natural Variation of Drug Susceptibility in Wild-Type Human Immunodeficiency Virus Type 1 , 2004, Antimicrobial Agents and Chemotherapy.

[48]  H. Mitsuya,et al.  Spirodiketopiperazine-Based CCR5 Inhibitor Which Preserves CC-Chemokine/CCR5 Interactions and Exerts Potent Activity against R5 Human Immunodeficiency Virus Type 1 In Vitro , 2004, Journal of Virology.

[49]  Andreas Sewing,et al.  Development and Automation of a 384-Well Cell Fusion Assay to Identify Inhibitors of CCR5/CD4-Mediated HIV Virus Entry , 2004, Journal of biomolecular screening.

[50]  T. Sakmar,et al.  Small-molecule antagonists of CCR5 and CXCR4: a promising new class of anti-HIV-1 drugs. , 2004, Current pharmaceutical design.

[51]  J. Lachowicz,et al.  Piperazine-based CCR5 antagonists as HIV-1 inhibitors. IV. Discovery of 1-[(4,6-dimethyl-5-pyrimidinyl)carbonyl]- 4-[4-[2-methoxy-1(R)-4-(trifluoromethyl)phenyl]ethyl-3(S)-methyl-1-piperazinyl]- 4-methylpiperidine (Sch-417690/Sch-D), a potent, highly selective, and orally bioavailable CCR5 antagonis , 2004, Journal of medicinal chemistry.

[52]  J. Weinberg.  Is resistance futile? , 2005, Cutis.

[53]  S. Piscitelli,et al.  Pharmacokinetics and Short-Term Safety of 873140, a Novel CCR5 Antagonist, in Healthy Adult Subjects , 2005, Antimicrobial Agents and Chemotherapy.

[54]  T. Kenakin,et al.  The CCR5 Receptor-Based Mechanism of Action of 873140, a Potent Allosteric Noncompetitive HIV Entry Inhibitor , 2005, Molecular Pharmacology.